Form 4: Ankit Mahadevia Reports Acquisition of 20,000 Spero Therapeutics Shares

Director Ankit Mahadevia reports acquiring 20,000 shares of Spero Therapeutics common stock through restricted stock units.

Summary

• On May 29, 2024, Ankit Mahadevia, a director of Spero Therapeutics, Inc. (SPRO), acquired 20,000 shares of common stock through restricted stock units (RSUs).
• These RSUs vest on May 29, 2025, contingent upon continued service.
• Following the transaction, Mahadevia beneficially owns 764,997 shares, including 65,817 shares held by the Mahadevia-Mehta Family Trust, where he serves as a trustee.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it simply reports an insider transaction. The acquisition of shares by a director is generally viewed positively, but without additional context, the impact is limited.

Positives

• The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future prospects.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in the pharmaceutical industry. Monitoring such transactions can provide insights into management's sentiment regarding the company's prospects.

Stakeholder Impact

• The transaction could have a slightly positive impact on shareholders, as insider buying often signals confidence in the company's future.

Key Dates